TP53 and acute myeloid leukemia: In addition, this comprehensive study analyzed the clinical features and prognostic impact of mutations and suggested alternative risk stratification of AML patients by inclusion of DNMT3A, MLL-PTD and TP53 genes in the proposed European Leukemia Net (ELN) system [35,36].